Onconetix Inc
ONCO
Company Profile
Business description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Contact
201 East Fifth Street
Suite 1900
CincinnatiOH45202
USAT: +1 513 620-4101
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,875.30 | 60.00 | 0.68% |
CAC 40 | 7,808.17 | 21.12 | -0.27% |
DAX 40 | 24,160.64 | 94.67 | -0.39% |
Dow JONES (US) | 44,459.65 | 88.14 | 0.20% |
FTSE 100 | 8,998.06 | 56.94 | 0.64% |
HKSE | 24,445.99 | 242.67 | 1.00% |
NASDAQ | 20,640.33 | 54.80 | 0.27% |
Nikkei 225 | 39,678.02 | 218.40 | 0.55% |
NZX 50 Index | 12,689.63 | 10.94 | 0.09% |
S&P 500 | 6,268.56 | 8.81 | 0.14% |
S&P/ASX 200 | 8,630.30 | 59.90 | 0.70% |
SSE Composite Index | 3,506.22 | 13.43 | -0.38% |